NCT07195383 GUSS-ICU Safe Nutrition Program After Extubation in ICU Patients
| NCT ID | NCT07195383 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Istanbul University - Cerrahpasa |
| Condition | Dysphagia |
| Study Type | INTERVENTIONAL |
| Enrollment | 82 participants |
| Start Date | 2025-03-05 |
| Primary Completion | 2026-03-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 82 participants in total. It began in 2025-03-05 with a primary completion date of 2026-03-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to evaluate the effects of using the GUSS-ICU Safe Nutrition Program after extubation in Intensive Care Unit patients. This randomized controlled trial will be conducted in the Anesthesia Intensive Care Unit of Bakırköy Dr. Sadi Konuk Training and Research Hospital. Eligible participants will be randomly assigned to either the control group (usual care/routine follow-up group) or the intervention group (GUSS-ICU patients). Patients undergoing GUSS-ICU assessment will continue the nutritional program, as directed by the scale, for four days. Data are recorded on the first and last day. The data will then be evaluated in conjunction with the control group data.
Eligibility Criteria
Inclusion Criteria: Age 18 and over Patients expected to remain intubated for more than 24 hours. Patients who have been extubated for no more than 4 hours. Exclusion Criteria: * Patients with neuromuscular disease * Patients requiring non-invasive ventilation for more than 6 hours after extubation * Patients being followed in the terminal phase * Patients with a tracheostomy cannula * Patients with a history of dysphagia * Patients with head/neck cancer or surgery * Patients with existing facial fractures * Patients with a RASS score not within the 0-2 range * Patients at high risk of bleeding (INR ≥ 2.0, Platelet count ≤ 50,000).
Contact & Investigator
Merve TURKAY
PRINCIPAL INVESTIGATOR
Istanbul Universitesi-Cerrahpasa
Frequently Asked Questions
Who can join the NCT07195383 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Dysphagia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07195383 currently recruiting?
Yes, NCT07195383 is actively recruiting participants. Contact the research team at turkay_merve@hotmail.com for enrollment information.
Where is the NCT07195383 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye), Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT07195383 clinical trial?
NCT07195383 is sponsored by Istanbul University - Cerrahpasa. The principal investigator is Merve TURKAY at Istanbul Universitesi-Cerrahpasa. The trial plans to enroll 82 participants.